Pharmacogenomics for the forensic toxicologist

Journal of Analytical Toxicology

Volumn 30, Issue 2, 2006, Pages 65-72

  Kupiec, Thomas C ^a   Raj, Vishnu ^a   Vu, Nicole ^a  

^a Analytical Research Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARDIAC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DEBRISOQUINE; ERYTHROMYCIN; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; METHADONE; MEXILETINE; NAPROXEN; OXYCODONE; PARACETAMOL; PROPRANOLOL; PROTEINASE INHIBITOR; THEOPHYLLINE; TOLBUTAMIDE; TRAMADOL; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

DRUG BLOOD LEVEL; DRUG METABOLISM; FORENSIC IDENTIFICATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENOMICS; REVIEW;

EID: 33644987397     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.2.65     Document Type: Review

References (48)

1. W.E. Evans and M.V. Relling. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491 (1999).
2. R. Nagasubramanian, F. Innocenti, and M.J. Ratain. Pharmacogenetics in cancer treatment. Annu. Rev. Med. 54: 437-452 (2003).
3. Pharmacogenomics: Applications to Patient Care, W.L. Allen, J.A. Johnson, D.L. Knoell, J.M. Kolesar, M.D. McInerney, H.L. McLeod, H.T. Spencer, and J.A. Tami, Eds. American College of Clinical Pharmacy, Kansas City, MO, 2004.
4. W.E. Evans. Pharmacogenomics: marshalling the human genome to individualize drug therapy. Gut 52(Suppl 2): 10-8 (2003).
5. D.A. Fishbain, D. Fishbain, J. Lewis, R.B. Cutler, B. Cole, H.L. Rosomoff, and R.S. Rosomoff. Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? Pain Med. 5(1): 81-93 (2004).
6. W.E. Evans and H.L. McLeod. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6): 538-549 (2003).
7. W.E. Evans and M.V. Relling. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990): 464-468 (2004).
8. C.A. Prows and D.R. Prows. Medication selection by genotype: How genetics is changing drug prescribing and efficacy. Am. J. Nurs. 104(5): 60-70 (2004).
9. M.W. Linder, R.A. Prough, and R. Valdes, Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43(2): 254-266 (1997).
10. M. Ingelman-Sundberg. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250(3): 186-200 (2001).
11. Pharmacogenomics: The Search for Individualized Therapies, J. Licinio and M.L. Wong, Eds. Wiley-VCH, Weinheim, Germany, 2002.
12. M.K. Ma, M.H. Woo, and H.L. McLeod. Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59(21): 2061-2069 (2002).
13. N. Poolsup, A. Li Wan Po, and T.L. Knight. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25(3): 197-220 (2000).
14. C.R. Lee, J.A. Goldstein, and J.A. Pieper. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12(3): 251-263 (2002).
15. Y. Gasche, Y. Daali, M. Fathi, A. Chiappe, S. Cottini, P. Dayer, and J. Desmeules. Codeine intoxication associated with ultrarapid CYP 2D6 metabolism. N. Engl. J. Med. 351(27): 2827-2831(2004).
16. M. Ingelman-Sundberg. Genetic polymorphisms of cytochrome P450 2D6 (CYP 2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1): 6-13 (2005).
17. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, F.M. Farin, and A.E. Rettie. Association between CYP 2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy . J. Am. Med. Assoc. 287(13): 1690-1698 (2002).
18. J. Van der Weide, L.S. Steijns, M.J. van Weelden, and K. de Haan. The effect of genetic polymorphism of cytochrome P450 CYP 2C9 on phenytoin dose requirement. Pharmacogenetics 11(4): 287-291(2001).
19. J. Kirchheiner and J. Brockmoller. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77(1): 1-16 (2005).
20. L.S. Wang, G. Zhou, B. Zhu, J. Wu, J.G. Wang, A.M. Abd El-Aty, T Li, J. Liu, T.L. Yang, D. Wang, X.Y. Zhong, and H.H. Zhou. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharmacol. Ther. 75(3): 191-197 (2004).
21. L. Wojnowski. Genetics of the variable expression of CYP 3A in humans. Ther. Drug Monit. 26(2): 192-199 (2004).
22. R. Weinshilboum. Inheritance and drug response. N. Engl. J. Med. 348(6): 529-537 (2003).
23. P. Song, S. Li, B. Meibohm, A.O. Gaber, M.R. Honaker, M. Kotb, and C.R. Yates. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci. 4(4): E29 (2002).
24. J. Lotsch, C. Skarke, J. Liefhold, and G. Geisslinger. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 43(14): 983-1013 (2004).
25. J.W. Holloway, P.R. Dunbar, G.A. Riley, G.M. Sawyer, P.F. Fitzharris, N. Pearce, G.S. Le Gros, and R. Beasley. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin. Exp. Allergy 30(8): 1097-1103 (2000).
26. W. Lee, A.C. Lockhart, R.B. Kim, and M.L. Rothenberg. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10(2): 104-111 (2005).
27. S. Ozawa, A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, S. Koyano, K. Sai, Y. Ohno, Y. Saito, and J. Sawada. Ethnic differences in genetic polymorphisms of CYP 2D6, CYP 2C19, CYP 3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 19(2): 83-95 (2004).
28. M. Radel and D. Goldman. Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism. Drug Metab. Dispos. 29(4 Pt 2): 489-494 (2001).
29. O. Tribut, Y. Lessard, J.M. Reymann, H. Allain, and D. Bentue-Ferrer. Pharmacogenomics. Med. Sci. Monit. 8(7): RA152-163 (2002).
30. O.Q. Yin, B. Tomlinson, M.M. Waye, A.H. Chow, and M.S. Chow. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14(12): 841-850 (2004).
31. H. Druid and P. Holmgren. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J. Forensic Sci. 42(1): 79-87 (1997).
32. J.E. Clarkson, J.M. Lacy, C.L. Fligner, N. Thiersch, J. Howard, R.C. Harruff, and B.K. Logan. Tramadol (Ultram) concentrations in death investigation and impaired driving cases and their significance. J. Forensic Sci. 49(5): 1101-1105 (2004).
33. A. Levo, A. Koski, I. Ojanpera, E. Vuori, and A. Sajantila. Postmortem SNP analysis of CYP 2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci. Int. 135(1): 9-15 (2003).
34. H. Druid, P. Holmgren, B. Carlsson, and J. Ahlner. Cytochrome P450 2D6 (CYP 2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. Forensic Sci. Int. 99(1): 25-34 (1999).
35. P.J. Jannetto, S.H. Wong, S.B. Gock, E. Laleli-Sahin, B.C. Schur, and J.M. Jentzen. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J. Anal. Toxicol. 26(7): 438-447 (2002).
36. K.E. Goeringer, L. Raymon, G.D. Christian, and B.K. Logan. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J. Forensic Sci. 45(3): 633-48 (2000).
37. A. Jonsson, P. Holmgren, and J. Ahlner. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci. Int. 143(1): 53-59 (2004).
38. C. Charlier, F. Broly, M. Lhermitte, E. Pinto, M. Ansseau, and G. Plomteux. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther. Drug Monit. 25(6): 738-742 (2003).
39. F.R. Sallee, C.L. DeVane, and R.E. Ferrell. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J. Child Adolesc. Psychopharmacol. 10(1): 27-34 (2000).
40. B.C. Wolf, W.A. Lavezzi, L.M. Sullivan, and L.M. Flannagan. Methadone-related deaths in Palm Beach County. J. Forensic Sci. 49(2): 375-378 (2004).
41. I. Mikolaenko, C.A. Robinson, Jr., and G.G. Davis. A review of methadone deaths in Jefferson County, Alabama. Am. J. Forensic Med. Pathol. 23(3): 299-304 (2002).
42. A. Gagajewski and F.S. Apple. Methadone-related deaths in Hennepin County, Minnesota: 1992-2002. J. Forensic Sci. 48(3): 668-671 (2003).
43. C.M. Milroy and A.R. Forrest. Methadone deaths: a toxicological analysis. J. Clin. Pathol. 53(4): 277-281 (2000).
44. S.H. Wong, M.A. Wagner, J.M. Jentzen, C. Schur, J. Bjerke, S.B. Gock, and C.C. Chang. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? J. Forensic Sci. 48(6): 1406-1415 (2003).
45. Y. Bezie, V. Talon, A. Lillo, C. Illier, E. Billaud, P. Prognon, and P. Boutouyrie. Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening. Ther. Drug Monit. 26(3): 271-276 (2004).
46. S. Begre, U. von Bardeleben, D. Ladewig, S. Jaquet-Rochat, L. Cosendai-Savary, K.P. Golay, M. Kosel, P. Baumann, and C.B. Eap. Paroxetine increases steady-state concentrations of (R)-methadone in CYP 2D6 extensive but not poor metabolizers . J. Clin. Psychopharmacol. 22(2): 211-215 (2002).
47. J.M. White and R.J. Irvine. Mechanisms of fatal opioid overdose. Addiction 94(7): 961-972 (1999).
48. G. Perret, J.J. Deglon, M.J. Kreek, A. Ho, and R. La Harpe. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction 95(11): 1647-1653 (2000).